Skip to main content
SpringerLink
Log in

Reply to comments from Vincent et al.

  • Letter to the Editor
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

The Original Article was published on 01 December 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tamura K, Kawai Y, Kiguchi T et al (2016) Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol 21:996–1003

    Article  CAS  PubMed  Google Scholar 

  2. Cairo MS, Coiffier B, Reiter A et al (2010) Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 149:578–586

    Article  CAS  PubMed  Google Scholar 

  3. Jones GL, Will A, Jackson GH et al (2015) Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol 169:661–671

    Article  PubMed  Google Scholar 

  4. Hira D, Chisaki Y, Noda S et al (2015) Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology 96:90–98

    Article  CAS  PubMed  Google Scholar 

  5. Mayer MD, Khosravan R, Vernillet L et al (2005) Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther 12:22–34

    Article  PubMed  Google Scholar 

  6. The Japanese Societyof Medical Oncology (ed) (2013) Clinical practice guideline for tumor lysis syndrome. Kanehara Shuppan, Tokyo

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Medical Research Center, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan

    Kazuo Tamura

Authors
  1. Kazuo Tamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuo Tamura.

Ethics declarations

Conflict of interest

No author has any conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tamura, K. Reply to comments from Vincent et al. . Int J Clin Oncol 22, 607–608 (2017). https://doi.org/10.1007/s10147-017-1093-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-017-1093-2

Keywords

Search

Navigation